CEL-SCI prices $1.35M common stock offering at $1.70/share; net proceeds ~$1.12M to fund Multikine/LEAPS

CEL SCI CORP

Offering of 794,117 shares at $1.70 per share; gross proceeds ~$1.35M, net ~$1.12M after discounts and expenses.
Spartan Capital Securities acting as sole book-running manager; 30-day over-allotment option for up to 119,117 additional shares.
Expected to close on or about May 2, 2023; proceeds to fund continued development of Multikine and LEAPS and general corporate purposes.
Offered under effective shelf registration S-3 (No. 333-265995) declared effective July 15, 2022; prospectus supplement filed April 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CEL SCI CORP entered into Underwriting Agreement with Spartan Capital Securities, LLC valued at approximately $1,119,000 (effective 2023-04-27).

Action: entry
Agreement: underwriting
Counterparty: Spartan Capital Securities, LLC
Value: approximately $1,119,000
Effective: 2023-04-27

Exact text from the filing

On April 27, 2023, CEL-SCI Corporation (the “Company”) entered into an Underwriting Agreement with Spartan Capital Securities, LLC as Representative of the several underwriters, pursuant to which the Company agreed to issue and sell 794,117 shares of common stock at a public offering price of $1.70 per share.

View on SEC.gov

800 material agreements filed in the last 30 days. Browse all material agreements →

CEL SCI CORP filing history →

Source: SEC EDGAR

accession 0001654954-23-005494

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.